Insiders who reported open-market trades in the last 12 months at the companies Paul A. Mahon files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Martine A. Rothblatt - $798.23M in UTHR purchases and sales in the last 12 months
James Edgemond - $201.52M in UTHR purchases and sales in the last 12 months
Michael Benkowitz - $135.23M in UTHR purchases and sales in the last 12 months
Christopher Patusky - $2.73M in UTHR purchases and sales in the last 12 months
Ray Kurzweil - $2.40M in UTHR purchases and sales in the last 12 months
Tommy G. Thompson - $2.06M in UTHR purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Paul A. Mahon is a corporate insider, tracked as EVP & GENERAL COUNSEL of UNITED THERAPEUTICS Corp (UTHR). InsiderAlpha holds 43 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Paul A. Mahon submitted recently?
5 primary Form 4 filings in the last 90 days, covering 1 company.
Has Paul A. Mahon been buying or selling stock?
Recorded transactions: 0 open-market purchases and 276 open-market sales ($154.27M) across all tracked filings.
Paul A. Mahon is EVP & GENERAL COUNSEL of UNITED THERAPEUTICS Corp (UTHR). 43 SEC Form 4 filings on record going back to 2024, most recently on 1 October 2026. Most recent open-market trade: sold $92K of UTHR on 1 October 2026. Lifetime open-market sales: $154.27M.
Recent transactions
20
The latest 20 SEC Form 4 transactions reported by Paul A. Mahon.
InsiderAlpha's records for Paul A. Mahon go back to 2024: 43 primary Form 4 filings, an average of 14.3 per year. 256 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
